Europe News
Filter News
Found 82,971 articles
-
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
-
BioSpace Movers & Shakers, Oct. 18
10/18/2019
Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers. -
Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019
10/18/2019
Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians' annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana.
-
Growth of Heart Defect Closure Devices Market to be Impacted by the Use of 3D Imaging in Heart Defect Closure Procedures | Technavio
10/18/2019
The report, heart defect closure devices market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.
-
Growth of Spasticity Treatment Market to Be Impacted by Advent of Neurostimulation Devices | Technavio
10/18/2019
The report, spasticity treatment market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.
-
Growth of HDAC (Histone Deacetylase) Inhibitors Market to be Impacted by Increasing Awareness About Cancer | Technavio
10/18/2019
The report, HDAC (histone deacetylase) inhibitors market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on RoA and geography for the forecast period 2019-2023.
-
Growth of Permanent Artificial Skin Market to be impacted by the Increasing Initiatives to Raise Awareness About Skin and Tissue Donation | Technavio
10/18/2019
The report, permanent artificial skin market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on end-user and geography for the forecast period 2019-2023.
-
Growth of PARP (Poly ADP-ribose Polymerase) Inhibitors Market to be Impacted by Expanded Application of PARP Inhibitors | Technavio
10/18/2019
The report, PARP (poly ADP-ribose polymerase) inhibitors market 2019-2023, has been added to Technavio's catalog.
-
Growth of Interstitial Cystitis Drugs Market to be impacted by the Advent of Gene Therapy | Technavio
10/18/2019
The report, interstitial cystitis drugs market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.
-
Growth of Ventricular Drainage Devices Market to Be Impacted by the Rising Adoption of Robot-assisted Neurosurgery | Technavio
10/18/2019
The report, global ventricular drainage devices market, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/18/2019
ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.
-
Growth of Liver Cancer Drugs Market to Be Impacted by the Introduction of Precision Cancer Medicine | Technavio
10/18/2019
The report, liver cancer drugs market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type (immunotherapy and targeted therapy) and geography (APAC, Americas, and EMEA) for the forecast period 2019-2023.
-
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age
10/18/2019
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor), to include use in infants with cystic fibrosis (CF) ages 6 months to less than 12 months who have one of the following mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
-
Growth of Pulmonary Edema Therapeutics To Be Impacted by the Increasing Use of Biomarkers for Disease Diagnosis | Technavio
10/18/2019
The report, global pulmonary edema therapeutics market, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share, as well as market segmentation based on type and geography for the forecast period 2019-2023.
-
Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products
10/18/2019
Concept Medical B.V. with its headquarters in Tampa, Florida has announced that on 16th October 2019, they have received the CE certification for their MagicTouch group of products.
-
Nordic Nanovector ASA - Key Information Regarding Potential Repair Offering
10/18/2019
Reference is made to the announcement by Nordic Nanovector ASA on 18 October 2019 concerning a private placement with gross proceeds in the amount of NOK 242 525 624 and that the Company is considering to conduct a repair offering of up to 2,204,778 new shares with non-tradeable subscription rights to eligible shareholders.
-
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
10/18/2019
Isofol Medical AB, announced the successful completion of Japan's Pharmaceutical and Medical Devices Agency review of the Clinical Trial Notification, allowing the start of the pivotal Phase 3 AGENT clinical study in metastatic colorectal cancer at Japanese sites.
-
Getinge Q3 2019 Result: Continued Growth and Improved Margins
10/18/2019
We continue to show strong organic sales growth and improved margins in the third quarter", says Mattias Perjos, President & CEO at Getinge.
-
Growth of Breast Cancer Therapeutics Market to be Impacted by the Rise in Strategic Collaborations | Technavio
10/18/2019
The market will accelerate at a CAGR of close to 8% between 2019 and 2023
-
Nordic Nanovector - Private Placement Successfully Completed - Oct. 18, 2019
10/18/2019
The Company announces that it has raised NOK 242,525,624 in gross proceeds through a private placement of 11,023,892 new shares The Private Placement was completed at a subscription price of NOK 22.00 per share, which was determined through an accelerated book-building process.